Literature DB >> 14744806

Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones.

Silvia Di Angelantonio1, Giorgio Bernardi, Nicola B Mercuri.   

Abstract

1. The effects of donepezil, one of the most common cholinesterase inhibitors used for treatment of Alzheimer's disease, were studied on nicotinic receptors (nAChRs)-mediated postsynaptic currents, in dopaminergic neurons of the substantia nigra pars compacta, using the patch-clamp recording technique in slice preparations. 2. Donepezil (10-100 microM) selectively and reversibly depressed nicotine currents, induced by brief puffer pulses, through a glass micropipette positioned above the slice. 3. The peak amplitude fading of the responses generated by repeated test applications of low doses of nicotine was accelerated by donepezil, while it slowed the recovery of nicotine currents after a large, desensitising, dose of the same agonist. 4. Donepezil depressed even maximal responses to nicotine, revealing a noncompetitive mechanism of action; moreover, the inhibition of nAChRs was voltage and time independent. 5. Pretreatment with vesamicol or methamidophos did not prevent the reduction of nicotine-induced currents. The data indicated direct effect on nAChR, independent from the activity of donepezil as cholinesterase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744806      PMCID: PMC1574242          DOI: 10.1038/sj.bjp.0705660

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Presynaptic muscarinic (M3) receptors reduce excitatory transmission in dopamine neurons of the rat mesencephalon.

Authors:  P Grillner; A Bonci; T H Svensson; G Bernardi; N B Mercuri
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

2.  Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas.

Authors:  J A Dani; K A Radcliffe; V I Pidoplichko
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

Review 3.  Pharmacotherapy for Alzheimer's disease: progress and prospects.

Authors:  Alan M Palmer
Journal:  Trends Pharmacol Sci       Date:  2002-09       Impact factor: 14.819

4.  Imaging of intracellular calcium during desensitization of nicotinic acetylcholine receptors of rat chromaffin cells.

Authors:  L Khiroug; R Giniatullin; E Sokolova; M Talantova; A Nistri
Journal:  Br J Pharmacol       Date:  1997-12       Impact factor: 8.739

5.  Modulation of neuronal nicotinic acetylcholine receptors by halothane in rat cortical neurons.

Authors:  T Mori; X Zhao; Y Zuo; G L Aistrup; K Nishikawa; W Marszalec; J Z Yeh; T Narahashi
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

Review 6.  Neuronal nicotinic receptors in the human brain.

Authors:  D Paterson; A Nordberg
Journal:  Prog Neurobiol       Date:  2000-05       Impact factor: 11.685

7.  Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.

Authors:  D Aarsland; K Laake; J P Larsen; C Janvin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

8.  Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

Authors:  Marek Samochocki; Anja Höffle; Andreas Fehrenbacher; Ruth Jostock; Jürgen Ludwig; Claudia Christner; Martin Radina; Marion Zerlin; Christoph Ullmer; Edna F R Pereira; Hermann Lübbert; Edson X Albuquerque; Alfred Maelicke
Journal:  J Pharmacol Exp Ther       Date:  2003-03-20       Impact factor: 4.030

9.  Acetylcholine receptor desensitization induced by nicotine in rat medial habenula neurons.

Authors:  R A Lester; J A Dani
Journal:  J Neurophysiol       Date:  1995-07       Impact factor: 2.714

10.  Tacrine interacts with an allosteric activator site on alpha 4 beta 2 nAChRs in M10 cells.

Authors:  A L Svensson; A Nordberg
Journal:  Neuroreport       Date:  1996-09-02       Impact factor: 1.837

View more
  8 in total

1.  Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report.

Authors:  Mehmet Sofuoglu; Aryeh I Herman; Yisheng Li; Andrew J Waters
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

2.  Functional connectivity and cognitive changes after donepezil treatment in healthy participants.

Authors:  P Péran; A S Salabert; T Dondaine; X Leclerc; H Gros-Dagnac; J-P Ranjeva; R Lopes; L Lanteaume; O Blin; C Thalamas; R Bordet; P Payoux
Journal:  Psychopharmacology (Berl)       Date:  2021-08-09       Impact factor: 4.530

3.  Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells.

Authors:  Jharna R Das; Yousef Tizabi
Journal:  Neurotox Res       Date:  2009-03-20       Impact factor: 3.911

Review 4.  Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Authors:  Chris G Parsons; Wojciech Danysz; Andrzej Dekundy; Irena Pulte
Journal:  Neurotox Res       Date:  2013-05-09       Impact factor: 3.911

5.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

Review 6.  Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Authors:  Ondrej Soukup; Michael Winder; Uday Kumar Killi; Vladimir Wsol; Daniel Jun; Kamil Kuca; Gunnar Tobin
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.

Authors:  Yichang Huang; Mhd Wasem Alsabbagh
Journal:  Pharmacol Res Perspect       Date:  2020-08

8.  Curcumin Potentiates α7 Nicotinic Acetylcholine Receptors and Alleviates Autistic-Like Social Deficits and Brain Oxidative Stress Status in Mice.

Authors:  Petrilla Jayaprakash; Dmytro Isaev; Waheed Shabbir; Dietrich E Lorke; Bassem Sadek; Murat Oz
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.